Gabel Joshua, Jabo Brice, Patel Sheela, Kiang Sharon, Bianchi Christian, Chiriano Jason, Teruya Theodore, Abou-Zamzam Ahmed M
Department of Cardiovascular and Thoracic Surgery, Loma Linda University Medical Center, Loma Linda, CA.
Department of Cardiovascular and Thoracic Surgery, Loma Linda University Medical Center, Loma Linda, CA.
Ann Vasc Surg. 2017 Oct;44:261-268. doi: 10.1016/j.avsg.2017.04.046. Epub 2017 May 15.
Society for Vascular Surgery practice guidelines for the medical treatment of intermittent claudication give a GRADE 1A recommendation for smoking cessation. Active smoking is therefore expected to be low in patients suffering from intermittent claudication selected for vascular surgical intervention. The aim of this study is to evaluate the prevalence of smoking in patients undergoing intervention for intermittent claudication at the national level and to determine the relationship between smoking status and intervention.
The Vascular Quality Initiative (VQI) registries for infra-inguinal bypass, supra-inguinal bypass, and peripheral vascular intervention (PVI) were queried to identify patients who underwent invasive treatment for intermittent claudication. Patient factors, procedure type (bypass versus PVI), and level of disease (supra-inguinal versus infra-inguinal) were evaluated for associations with smoking status (active smoking or nonsmoking) by univariate and covariate analysis.
Between 2010 and 2015, 101,055 procedures were entered in the 3 registries, with 40,269 (40%) performed for intermittent claudication. Complete data for analysis were present in 37,632 cases. At the time of intervention, 44% of patients were active smokers, with wide variation by regional quality group (16-53%). In covariate analysis, active smoking at treatment was associated with age <70 years (prevalence ratio [PR] 2.42), male gender (PR 1.03), chronic obstructive pulmonary disease (PR 1.35), absence of prior cardiovascular procedures (PR 1.15), poor medication usage (PR 1.10), preoperative ankle-brachial index (ABI) <0.9 (PR 1.19), and supra-inguinal disease (PR 1.14). Invasiveness of treatment (PVI versus bypass procedures) was not significantly associated with smoking status. During follow-up, 36% of patients had quit smoking. Predictors of smoking cessation included age ≥70 years (RR 1.45), ABI ≥0.9 (RR 1.12), and bypass procedures (RR 1.22).
At the time of treatment, 44% of patients undergoing intervention for intermittent claudication in the VQI were active smokers and there was a wide regional variation. Prevalence of active smoking was greater in the presence of younger age, fewer comorbidities, lower ABI, and supra-inguinal disease. Type of procedure performed, and in turn level of invasiveness required, did not appear to be influenced by smoking status. Elderly patients and those undergoing open procedures were more likely to quit smoking during follow up. These findings suggest opportunities for greater smoking cessation efforts before invasive therapies for intermittent claudication.
血管外科学会关于间歇性跛行药物治疗的实践指南对戒烟给出了1A级推荐。因此,预计接受血管外科手术干预的间歇性跛行患者中主动吸烟率较低。本研究的目的是评估全国范围内接受间歇性跛行干预治疗患者的吸烟率,并确定吸烟状况与干预之间的关系。
查询血管质量倡议(VQI)登记处的腹股沟下旁路手术、腹股沟上旁路手术和外周血管介入(PVI)的记录,以确定接受间歇性跛行侵入性治疗的患者。通过单因素和协变量分析,评估患者因素、手术类型(旁路手术与PVI)和疾病水平(腹股沟上与腹股沟下)与吸烟状况(主动吸烟或不吸烟)之间的关联。
2010年至2015年期间,3个登记处共录入了101,055例手术,其中40,269例(40%)是针对间歇性跛行进行的。37,632例病例有完整的分析数据。在进行干预时,44%的患者为主动吸烟者,各地区质量组之间差异很大(16%-53%)。在协变量分析中,治疗时主动吸烟与年龄<70岁(患病率比[PR]2.42)、男性(PR 1.03)、慢性阻塞性肺疾病(PR 1.35)、既往无心血管手术史(PR 1.15)、药物使用不佳(PR 1.10)、术前踝臂指数(ABI)<0.9(PR 1.19)以及腹股沟上疾病(PR 1.14)相关。治疗的侵入性(PVI与旁路手术)与吸烟状况无显著关联。在随访期间,36%的患者戒烟。戒烟的预测因素包括年龄≥70岁(RR 1.45)、ABI≥0.9(RR 1.12)和旁路手术(RR 1.22)。
在接受治疗时,VQI中接受间歇性跛行干预治疗的患者中有44%为主动吸烟者,且地区差异很大。主动吸烟率在年龄较小、合并症较少、ABI较低和腹股沟上疾病患者中更高。所进行的手术类型以及相应所需的侵入性水平似乎不受吸烟状况的影响。老年患者和接受开放性手术的患者在随访期间更有可能戒烟。这些发现表明在对间歇性跛行进行侵入性治疗之前有更大的戒烟努力机会。